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A promotional poster by the US Public Health Ser-
vice in cooperation with the American Society for Con-
trol of Cancer dated 1938 hangs in our conference room
and shows a rooster crowing at sunrise. The poster reads:
“Early is the Watch Word for Cancer Control; early diagno-
sis/early treatment will save many lives; early cancer can be
cured.”
It is obvious that the prerequisite for early treatment
is early diagnosis. Currently, it is soundly projected that
early diagnosis increases the survival of cancer patients by
ﬁve years, making it the best “treatment” alternative yet.
Currently, there are a number of in vitro (laboratory)
as well as in vivo (imaging) cancer diagnostics procedures
available. However, the speciﬁcity and sensitivity of many
of these tests are barely acceptable, and the diagnosis of
cancer is usually made with the aid of other parameters—
biopsy being the most deﬁnitive. More important, and
more relevant to this editorial, the diagnostic markers in
many of these cancer tests may not have anything to do
with cancer biology or etiology; they just happen to be
there. The best and well-known example is the prostate-
speciﬁc antigen (PSA) test for prostate cancer that mea-
sures PSA production (and hence its serum level) which
is elevated in individuals with large prostate, enlarged
prostate, or enlarging or inﬂamed prostate (by injury,
infection, cancer, etc). Although patients with prostate
cancer usually have elevated PSA levels, a majority of peo-
ple with abnormally high serum PSA levels do not have
prostate cancer.
On the treatment side, physicians generally consider
cancers that aﬀect each organ or group of organs as “dis-
tinct”diseases(eg,braintumor,prostatecancer,lungcan-
cer, colon cancer, breast cancer, ovarian cancer, etc). For
physicians, particularly surgeons, caring for cancer pa-
tients, this perspective makes a lot of sense because each
tumor presents itself diﬀerently and has diﬀerent impli-
cations and ramiﬁcations for individual patients. These
diﬀerences have a considerable impact on the strategy for
patient management. However, in drug discovery process,
one needs to be more open-minded and treat cancer as
a biological phenomenon with a mechanism of action
Figure 1. A promotional poster by the US Public Health Service
in cooperation with the American Society for Control of Cancer
dated 1938.
spanning overvarious“cancers.”Drugdiscoveryscientists
need not be restrictive toward any particular cancer, and
physicians need not be skeptical toward a pan approach
to cancer diagnosis and treatment. Scientists and physi-
cians alike need to actively consider prevention in their
approach for patient management.
Ideally, the goal of cancer patient management is to
tie the diagnosis with the treatment. We are working to-
ward this goal by continuing research and development
in which the diagnostic marker and therapeutic target is
the very same molecule. It is certainly possible to measure
serum and tissue levels of this molecule for diagnosis, to
target it for treatment, to examine it for prognosis, and
subsequentlyuseitforsurveillance,andevenuseittopre-
dict the aggressiveness of cancer and choose the treatment
option.176 Hossein A. Ghanbari 2004:4 (2004)
The diagnostic marker and therapeutic target in
our cancer discovery program is human aspartyl (as-
paraginyl) β-hydroxylase (HAAH). This enzyme is an α-
ketoglutarate-dependent deoxygenase that catalyzes post-
translational hydroxylation of β c a r b o n so fa s p a r t y la n d
asparaginyl residues present in epidermal-growth-factor
(EGF)-like domains of certain proteins, including notch
and notch homologues, which have known roles in
oncogenesis and cellular functions that propagate the
malignant phenotype. Experimental overexpression of
HAAH causes malignant transformation, and inhibition
of over-expression or inactivation of HAAH results in
normalization of malignant phenotypes. HAAH over-
expression correlates with motility of malignant neoplas-
tic cells; as such, it has a functional role in cell migration
or invasiveness—properties required for inﬁltrative and
metastatic tumor growth.
As a diagnostic marker, HAAH is found to be overex-
pressed in virtually every tissue of every cancer specimen
and absent in noncancer tissues (with the exception of
placental trophoblast cells) tested by immunohistochem-
ical (IHC) methods. Moreover, preliminary studies us-
ing sandwich ELISA for analysis of serum samples have
resulted in an assay speciﬁcity of 97% and sensitivity of
95%–100% (depending on the sample set). Gene expres-
sion analysis (RT-PCR or qRT-PCR) also has demon-
strated the overexpression of HAAH in virtually every
cancer tissue type tested and in none of the noncancer
specimens.
Beyond just a simple diagnostic marker, HAAH lev-
els could be used to predict the aggressiveness of can-
cer in the patient and guide the physician in choos-
ing an appropriate treatment option. In a recent study
by Takashi Maeda, MD, et al, “Clinicopathological Cor-
relates of Aspartyl (Asparaginyl) β-Hydroxylase Over-
Expression in Cholangiocarcinoma Cancer Detection and
Prevention,” it was demonstrated that HAAH expression
in surgically resected intrahepatic cholangiocarcinoma
signiﬁcantlycorrelatedwithtumorsize,growthtypes,dif-
ferentiation, vascular invasion, and poor prognosis after
surgery.
Further, HAAH has been proven, in principle, to be
a valid target for cancer therapeutic development. Its
relevance to cancer is well established by its biological
role and its presence in most cancer cells. Upon over-
expression, HAAH migrates to the cell surface and is
primarily present in the inﬁltrating periphery of the tu-
mor,makingitanaccessibletarget.Moreover,anti-HAAH
antibodies (both naked and bound to toxins) internal-
ize subsequent to binding to HAAH on the cell surface.
Also, anti-HAAH antibodies and antisense inhibit prolif-
eration, motility, and invasion in vitro and in vivo. Fi-
nally, in preliminary animal eﬃcacy studies, injection of
an anti-HAAH antibody has shown inhibition of growth
and metastasis of established human colon cancer in a
mouse xenograft model of human colon cancer metasta-
sized to the liver.
Aside from HAAH’s diagnostic and therapeutic value,
based on the biological role of HAAH and the molecule,
per se, it can be readily speculated that HAAH may be
used as a target for the prevention of cancer. Obvious ex-
amples of preventive measures would be passive and ac-
tive immunization for individuals at high risk. Again, the
preventative approach can be keyed to HAAH levels, par-
ticularly for the period of post-treatment or post-surgery
and other “at-risk” patients.
Many breakthroughs have been reported in the area
of cancer diagnostics, therapeutics, and even prevention.
Moreover, there has been a widespread tendency to com-
bine these approaches. However, true integration of these
approaches requires a common thread, and the discov-
erers and practitioners in oncology need to actively seek
that common thread. Here, I have highlighted HAAH as
a common thread to demonstrate that true integration of
diagnostics and therapeutics is a possibility and its pur-
suit should stand at the forefront of eﬀorts to manage and
eventually tame cancer.
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